2022 World Conference on Lung Cancer (ePosters)-EP08.02-007. Disease Burden and Clinical Outcomes of Advanced ROS1 Positive NSCLC with Different Fusion Partners

EP08.02-007. Disease Burden and Clinical Outcomes of Advanced ROS1 Positive NSCLC with Different Fusion Partners

Pdf Summary

This study aimed to investigate the disease burden and clinical outcomes of advanced ROS1 NSCLC with different fusion partners. The researchers collected data from 35 patients with advanced ROS1 NSCLC and identified the fusion partner through RT-PCR or NGS. They compared the disease burden and efficacy of crizotinib between CD74 and non-CD74 ROS1 NSCLC, as well as the progression pattern and resistance mechanism.<br /><br />The results showed that CD74-ROS1 NSCLC had a higher tendency to develop metastases in distant organs, especially in osseous tissues. There was no significant difference in the development of CNS metastases between CD74 and non-CD74 ROS1 NSCLC. In terms of treatment efficacy, for patients who received crizotinib as the initial ROS1-TKI, CD74-ROS1 NSCLC demonstrated similar progression-free survival (PFS) compared to non-CD74 ROS1 NSCLC.<br /><br />Furthermore, the researchers found that CD74-ROS1 NSCLC had a higher incidence of secondary mutations in the ROS1 kinase domain, with the G2032R mutation being the most common. This suggests that CD74-ROS1 NSCLC may be more prone to develop ROS1 secondary mutations.<br /><br />In conclusion, patients with CD74-ROS1 NSCLC had a higher likelihood of developing distant metastases, particularly in osseous tissues, and had a higher incidence of secondary mutations in the ROS1 kinase domain. However, the efficacy of crizotinib and the tendency to develop CNS progression were similar between CD74 and non-CD74 ROS1 NSCLC.

Asset Subtitle

Zihua Zou

Meta Tag

Speaker Zihua Zou

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

disease burden

clinical outcomes

advanced ROS1 NSCLC

fusion partners

crizotinib efficacy

CD74-ROS1 NSCLC

metastases

osseous tissues

CNS metastases

secondary mutations